Hot Stocks

The stock market changes from minute to minute, and what’s hot today may not be hot tomorrow. Our expert analysts spot hot stocks that are heating up before the crowd swoops in to bid prices higher, and our journalists sift through the noise to shine a light on trending investments -- in spaces ranging from quantum computing to marijuana stocks -- to determine whether they’re actually worth your time.

Only One Type of Investor Should Gamble on Nikola Stock Right Now

Nikola stock could rise further in the short-term amid euphoria about alternative energy and electric-vehicle makers. But does that make it a long-term buy?

Carnival’s Turnaround Is Near and CCL Stock Will Rally Further

Carnival's turnaround is near and CLL stock will rally. CCL stock is worth twice today's price and will be much higher by summer end.

The Bottom Line for Marijuana Stocks Now

Since the March 23 bottom, marijuana stocks are performing better than nine out of ten S&P sectors. There's a few things that might be going on here.

Why DraftKings Stock Will Make a Great Investment Later

Although DraftKings stock makes for a compelling long-term investment, now is probably not the right time to get involved.

It’s Time to Take Some Chips off the Table With Splunk Stock

Anticipate more upside but cash out your shares of Splunk stock anyway.

Wait for a Lower Price to Buy Autodesk

Even though ADSK stock has strong momentum, valuation matters and investors should be patient.

United Natural Foods Earnings: UNFI Stock Falls 16% Despite Q3 Beats

United Natural Foods earnings have UNFI stock crashing on Wednesday despite the company crushing EPS and revenue estimates from Wall Street.

Choppy Waters And Poor Visibility Make Carnival Stock A Rough Ride

The whole travel industry is in turmoil, but CCL stock is working to increase customer confidence while lowering expenses.

Does Realty Income’s 4.5% Dividend Yield Make It Worth Buying?

Realty Income stock is still down sharply from where it traded prior to the coronavirus. So are the shares worth picking up today?

Align Technology Has a Fundamental Gap

With the economy improving on paper, ALGN stock – which depends on a strong consumer base willing to pay for pricey orthodontic procedures – is initially appealing. However, investors should look at the fine print.

DocuSign Stock May Be Overdone, but It’s Still a Great Long-Term Buy

DocuSign stock soared as companies made arrangements to remotely share secure documents. But the stock looks like it's ready to take a break.

It’s Time for Relentless Facebook Stock to Take a Chill Pill

FB stock remains a buy on dips for as long as Facebook has billions of engaged and frequent users. It's nearly impossible to ruin such potential.

The 9 Best Cryptocurrencies to Watch for the Rest of 2020

Although the stock market has made waves recently, don’t forget to take a look at cryptocurrencies, which may enjoy a great year.

This Nikola Stock Run-up Could Very Well Just Be the Beginning

NKLA stock has been surging following the recent announcement by Nikola Motor on Badger, an upcoming electric pickup.

Luckin Coffee Has Rallied, But Will the Good Times Last?

LK stock bounced substantially higher following a devastating accounting scandal. However, it's fair to ask if shares have become far too overheated.

ROKU Stock Will Continue Benefitting From the TCL Partnership

Roku's strong operating system, along with its first-mover advantage, will prevent it from being hurt by its competitors. Investors should buy Roku stock.

How You Can Bank on Domino’s Pizza for Contactless Profits

DPZ stock may have stretched itself for the moment, but Domino’s contactless delivery makes it a relevant pick for the new normal.

Believe It or Not, There’s a Safe Way to Buy Nvidia Stock

Nvidia has been a market leader for more than a few good reasons and momentum which continues to build looking into 2020’s second half and beyond

Why iBio Stock Could Triple on Successful Vaccine Trials

The price of iBio stock could double, if not triple in value on successful trials, and on the potential for FDA approval in the near term.